DEF 14A: Voyager Therapeutics Announces 2024 Annual Meeting of Stockholders

Voyager Therapeutics will hold its 2024 Annual Meeting of Stockholders on June 5, 2024, to elect directors, approve executive compensation, and ratify the appointment of Ernst & Young LLP as its independent auditor.

Summary

• Voyager Therapeutics will hold its 2024 Annual Meeting of Stockholders on June 5, 2024, at its Lexington, Massachusetts offices.
• Stockholders of record as of April 8, 2024, are entitled to vote.
• The meeting's agenda includes the election of three Class III directors (Michael Higgins, Jude Onyia, and Nancy Vitale) to serve until the 2027 annual meeting.
• Additionally, stockholders will vote on a non-binding advisory resolution to approve executive compensation and to ratify the appointment of Ernst & Young LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2024.
• The company is providing proxy materials online, with a Notice of Internet Availability mailed to many stockholders starting April 25, 2024.
• Stockholders can vote online, by phone, or by mail.

Sentiment

Score: 7

Explanation: The document is primarily informational and procedural, with a neutral to slightly positive tone. The company is adhering to corporate governance best practices and demonstrating a commitment to ESG principles. The recent capital raise is a positive sign for the company's financial health.

Positives

• The company is taking steps to reduce costs and environmental impact by providing proxy materials online.
• The Board of Directors is recommending 'for' votes on all proposals.
• The company has a compensation recovery policy in place, effective as of October 2, 2023, in accordance with Nasdaq Listing Rule 5608.
• The company is committed to ESG principles, including environmental stewardship, social responsibility, and governance and ethics.

Negatives

• Peter Pfreundschuh, former Chief Financial Officer, resigned effective April 12, 2024, and will transition out of his employee position on May 5, 2024.
• Robert Hesslein, former Senior Vice President and General Counsel, resigned effective April 28, 2023.

Risks

• The document does not explicitly detail risks, but general business risks are inherent in the operations of a biopharmaceutical company.
• Failure to achieve corporate goals could impact executive compensation.
• The company's success depends on attracting, retaining, and motivating a diverse team of highly skilled employees at all levels.

Future Outlook

The document does not contain specific forward-looking statements regarding financial performance or product development milestones beyond the scope of the meeting's agenda.

Management Comments

• Alfred Sandrock, M.D., Ph.D., Chief Executive Officer, President and Director, signed the notice for the Annual Meeting.
• The Board of Directors believes that linking compensation to the achievement of nearand long-term business goals has helped drive the company's performance over time.
• The Board of Directors is committed to diversity, equity, inclusion, and belonging.

Industry Context

The document reflects standard corporate governance practices for a publicly traded biopharmaceutical company, including the election of directors, executive compensation, and auditor ratification.

Comparison to Industry Standards

• The peer group used for executive compensation benchmarking includes companies like 4D Molecular Therapeutics, Foghorn Therapeutics, and Stoke Therapeutics, indicating a focus on similar-sized biopharmaceutical companies with a comparable stage of product development.
• The director compensation structure, including annual retainers and committee fees, aligns with industry standards for publicly traded companies.
• The company's commitment to ESG principles and reporting is consistent with increasing investor expectations for corporate social responsibility.

Management Changes

Corporate Governance

Related Party Transactions

• Voyager has collaboration and license agreements with Neurocrine Biosciences, Inc., a beneficial owner of more than 5% of Voyager's voting securities.
• Voyager received cost reimbursement amounts from Neurocrine related to development costs under these agreements.
• As of December 31, 2023, Voyager had approximately $3.3 million in related party collaboration receivable associated with its collaborations with Neurocrine.
• During the years ended December 31, 2023 and 2022, Voyager recognized $90.6 million and $0.9 million of revenue, respectively, associated with its collaborations with Neurocrine.
• Neurocrine paid Voyager an upfront payment of approximately $136.0 million and approximately $39.0 million as consideration for an equity purchase of 4,395,588 shares of Voyager's common stock in February 2023.
• Certain 5% stockholders and their affiliates purchased shares of common stock and pre-funded warrants in the 2024 Public Offering.

Stakeholder Impact

• Shareholders are asked to vote on key corporate governance matters.
• Employees may be impacted by changes in executive leadership and compensation policies.
• The company's commitment to ESG principles may positively impact the community and environment.
• Patients may benefit from the company's research and development efforts in neurological diseases.

Next Steps

• Stockholders should review the proxy materials and vote on the proposals.
• The company will hold the Annual Meeting on June 5, 2024.
• The Board of Directors will consider the outcome of the advisory vote on executive compensation when making future compensation decisions.
• The Audit Committee will continue to oversee the company's financial reporting process and the work of the independent registered public accounting firm.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Board of Directors, Executive Compensation, Director Election, Ernst & Young, Stockholders, Corporate Governance, Voyager Therapeutics